MANGOCEUTICALS INC
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
MGRX$0.19-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Six Months Ended · For the Six Months Ended | ||||
|---|---|---|---|---|
| June 30, 2024 · June 30, 2023 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $(4,758,936) | $(4,844,910) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 9,429 | 12,306 | ||
| Issuance of common stock for services | 1,224,900 | 1,087,000 | ||
| Imputed interest expense | - | (6,473) | ||
| Options vested for stock-based compensation | 88,945 | 128,542 | ||
| Loss on sale of assets | 18,387 | - | ||
| Amortization of discount on preferred stock | 222,678 | - | ||
| (Increase) decrease in operating assets: | ||||
| Inventory | 4,482 | (23,494) | ||
| Prepaid expenses | 47,654 | (41,015)) | ||
| Operating lease right of use asset | 29,251 | 27,082 | ||
| (Decrease) increase in operating liabilities: | ||||
| Accounts payable and accrued liabilities | 577,885 | 96,530 | ||
| Operating lease right of use liabilities | (31,134) | (27,862) | ||
| Payroll tax liabilities | (1,908) | 3,408 | ||
| NET CASH USED IN OPERATING ACTIVITIES | (2,568,367) | (3,588,886) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchases of property and equipment | - | (3,519) | ||
| Sale of property and equipment | 65,000 | - | ||
| NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | 65,000 | (3,519) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from borrowings on notes payable to related parties | 187,500 | - | ||
| Proceeds from sales of common stock for cash | 568,270 | 5,000,000 | ||
| Proceeds from sales of preferred stock for cash | 1,500,000 | - | ||
| Proceeds from exercise of warrants | - | 1,024,500 | ||
| Repayment on notes payable | - | (78,260) | ||
| Repayment on notes payable - related party | - | (89,200) | ||
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 2,255,770 | 5,857,040 | ||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | ||||
| End of period | (247,597) | 2,264,635 | ||
| CASH AND CASH EQUIVALENTS: | ||||
| Beginning of period | 739,006 | 682,860 | ||
| Effects of currency translation on cash and cash equivalents | (1,166) | - | ||
| End of period | $490,243 | $2,947,495 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for income taxes | $ | - | $ | - |
| Cash paid for interest | $ | - | $ | - |
| Supplemental schedule of non-cash investing and financing activities: | ||||
| Issuance of Series C Convertible Preferred for patent acquisition | $14,610,000 | $ | - | |
| Series B Convertible Preferred converted to common stock | $390,500 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.